Clinical Significance of Haemostatic Tests in Chronic Liver Disease
Aida Saray, Rusmir Mesihovic, Nenad Vanis, Srdjan Gornjakovic, Dzanela Prohic
Med Arh. 2012; 66(4): 231-235
Objective: To determine different haemostatic tests in patients with various degrees of liver parenchymal damage and to rule out their role in assessing parenchymal hepatocyte dysfunction. Methods: Seventy-five patients with chronic liver disease were included and due to their degree of liver damage catego-rized into three groups: group one patients with chronic viral hepatitis and early stage of fibrosis (n=30), group two patients with compensated cirrhosis (n=17) and group three patients with decompensated liver cirrhosis (n=28). The following hae-mostatic tests were measured: activated partial thromboplastin time, prothrombin time, plasma fibrinogen, antithrombin III and protein C and plasma D-dimer. Re-sults: Antithrombin III levels showed significant reduction in compensated (83.86 ± 19.49%) and decompensated cirrhosis (52.64 ± 14.31%; p<0.001), while protein C activity exhibited significant decrease in all the patients group, including patients with chronic viral hepatitis (90.58 ± 11.03, 74.65± 19.56, 41.11 ± 18.35%; p<0.001) in comparison with controls. Correlation between antithrombin III (Pearson ro= -,931, p<0,01) and protein C (Pearson ro= -,789, p<0,01) and clinical degree of chronic liver disease were found. D-dimer levels were significantly increased in decompensated cirrhosis (832.26 ± 537.19 μg/L; p<0.001) and no significant difference was found in group two and three when compared with healthy controls. Conclusions: In advanced chronic liver disease anticoagulant activitiy may reflect hepatocellular dysfunction. Protein C activity may be used as a senstive marker of hepatocellular damage even in those patients with mild liver affection whereas D-dimer levels may be considered as an important sign of decompensation in cirrhotic patients. Further studies are necessary to approve whether these parameters could be used as clinical routine markers of hepatocyte function in chronic liver disease.
1. Mammen EF. Coagulation abnormalities in liver disease. Haematol Oncol Clin North Am. 1992; 6: 1247-1257.
2. McCormick PA, Murphy KM. Spleno- megaly, hypersplenism and coagulation abnormalities in liver disease. Bailliere’s Clin Gastroentrol. 2000; 14: 1009-1031.
3. Tacke F, Fied ler K, von Depka M, et a l. C l i nt t ic a l a nd prog nos t ic role of plasma coagulation factor XIII activity for bleeding disorders and 6-year sur- vival in patients with chronic liver dis- ease.Liver Int. 2006; 26: 173-181
4. Rodríguez-Iñigo E, Bartolomé J, Quiroga JA, Hedner U, Suárez A, Tomás JF, et al. Expression of factor VII in the liver of patients with liver disease: correlations with the disease severity and impairment in the hemostasis. Blood Coagul Fibrino- lysis. 2001 Apr; 12(3): 193-199.
5. Kerr R. New insights into haemostasis in liver failure. Blood Coagul. Fibrinolysis. 2003; 12(Suppl 1): S43-s45.
6. Hollstelle MJ, Geertzen HG, Straats- burg IH, Van Gulik TM, Van Mourik JA. Factor VIII expression in liver disease. Thromb. Haemost. 2004; 91: 267-275.
7. De Caterina M, Tarantino G, Farina C, Arena A, di Maro G, Esposito P, Sco- paca sa F. Haemosta sis u nba la nce i n Pugh-scored liver cirrhosis: character- istic changes of plasma levels of protein C versus preotein S. Haemostasis. 1993; 23: 229-235.
8. Kujovich JL.Haemostatic defects in end stage liver disease. Crit Care Clin. 2005; 21: 563-587.
9. Guersoy S, Baskol M, Torun E, Yurci A. et al. Importance of anticoagulant proteins in chronic liver disease Turk J Gastroen- terol. 2005; 16(3): 129-133.
10. Francis JL, Armstrong DJ. Aquired dys- fibrinogenaemia in liver disease. J Clin Path. 1982; 35: 667-672.
11. Tripodi A, Mannucci PM. Abnormali- ties of hemostasis in chronic liver dis- ease: reappraisal of their clinical sig- nificance and need for clinical and lab- oratory research. J Hepatol. 2007 Apr; 46(4): 727-733.
12. Al Ghumlas AK, Abdel Gader AG, Al Faleh FZ. Haemostatic abnormalities in liver disease: could some haemostatic tests be useful as liver function tests? Blood Coag u lat ion a nd Fibri nolysis.2005, 16: 329-335.
13. O ’G r ad y J G, L a n g l y P G, I s ol a L M, Aledort LM, Wiliams R. Coagulopathy of fulminant hepatic failure. Semin Liver Dis. 1986; 6: 159-163.
14. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F. et al. Histological grading and staging of chronic hepati- tis. J Hepatol. 1995 Jun; 22(6): 696-699.
15. Clauss A. Rapid physiological coagula- tion method in determination of fibrin- ogen. Acta Haematol. 1957; 17: 237-246.
16. Tripodi A. Hemostasis abnormalities in liver cirrhosis: myth or reality? Pol Arch Med Wewn. 2008 Jul-Aug; 118(7-8): 445-8. Review.
17. Polson J, Lee WM. American Association for the Study of Liver Disease. AASLD position paper: the management of acute l iver fa i lu re. Hepatolog y. 20 05 May; 41(5): 1179-1197.
18. Schepke M, Roth F, Fimmers R, Brens- ing KA, Sudhop T, Schild HH, Sauer- bruch T. Comparison of MELD, Child- Pugh, and Emory model for the predic- tion of survival in patients undergoing transjugular intrahepatic portosystemic shunting.Am J Gastroenterol. 2003 May; 98(5): 1167-1174.
19. Tripodi A, Mannucci PM. Abnormali- ties of hemostasis in chronic liver dis- ease: reappraisal of their clinical sig- nificance and need for clinical and lab- oratory research. J Hepatol. 2007 Apr; 46(4): 727-733.
20. Abdo AA, Sanai FM, Azzam N, Al Sawat K, Al Dukhayil M, Al Ghumlas A, et al. Natural anticoagulants can be useful predictors of severity in chronic liver disease. Blood Coagul Fibrinolysis. 2010 Mar; 21(2): 122-127.
21. 2Deitcher SR. Interpretation of the in- ter n at ion a l nor m a l i se d r at io i n pa- tients with liver disease. Lancet. 2002; 359: 47-48.
22. Mammen EF. Coagulation defects in liver disease. Med Clin North Am. 1994 May; 78(3): 545-554.
23. Forman LM, Lucey MR. Predicting the prognosis of chronic liver disease: an evolution from chi ld to MELD. Mayo End-s t age Liver Di sea se.Hepatolog y. 2001 Feb; 33(2): 473-475.
24. Al Ghumlas AK, Abdel Gader AG, Al Faleh FZ. Natural anticoagulants and fibrinolytic activity following interferon therapy in chronic viral hepatits. Blood Coagulation and Fibrinolysis. 2008, 19: 263-267.
25. Tr ipod i A, Ca ldwel l SH, Hof f ma n M, Trot ter JF, Sa nya l AJ. The prothrom- bin time test as a measure of bleeding risk and prognosis in liver disease. Ali- ment Pharmacol Ther. 2007 Jul 15; 26(2): 141-148.
26. Takahashi H, Tatewaki W, Wada K, Ni- wano H, Shibata A. Fibrinolysis and fi- brinogenolysis in liver disease. Am J He- matol. 1990 Aug; 34(4): 241-245.
27. Amitrano L, Guardascione MA, Brancac- cio V, Balzano A. Coagulation disorders in liver disease.Semin Liver Dis. 2002 Feb; 22(1): 83-96
28. Zocco MA, Di Stasio E, De Cristofaro R, Novi M, Ainora ME, Ponziani F, et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein throm- bosis development. J Hepatol. 2009 Oct; 51(4): 682-689.
29. Raya-Sánchez JM, Gonzá lez-Reimers E, Rodríguez-Martín JM, Santolaria- Fernández F, Molina-Pérez M, Rodrí- guez-Moreno F, et al. Coagulation inhib- itors in alcoholic liver cirrhosis. Alcohol. 1998 Jan; 15(1): 19-23.
30. Ktoczko J, Mian M, Wojtukiewicz MZ, Babiuch l, Bielawiec M, Galar M. Plasma protein C as a marker of hepatocellular damage in alcoholic liver disease. Hae- mostasis. 1992; 22: 340-344.
31. Dumontier I, Alhenc-Gelas M, Chatellier G, Brenet P, Aiach M, Petite JP. Changes in levels of blood coagulation inhibitors in cirrhosis. Prospective study in 33 pa- tients.Gastroenterol Clin Biol. 1992; 16(2): 120-125.
32. B el l H, O de ga a rd OR, A nder s s on T, Raknerud N. Protein C in patients with alcoholic cirrhosis and other liver dis- ea ses. J Hep at ol . 1992 Ma r; 14(2-3): 163-167.
33. Park CJ, Cho HI, Kim SI. A study on changes of coagulation inhibitors and fibrinolysis inhibitors in patients with liver cirrhosis and hepatoma.J Korean Med Sci. 1991 Mar; 6(1): 1-6.
34. Kato S, Kawasaki H. Blood coagulation and fibrinolysis in relation to endotox- emia in liver cirrhosis and hepatocellu- lar carcinoma. Nippon Shokakibyo Gak- kai Zasshi. 1995 Aug; 92(8): 1143-1148. 35. Agarwal S, Joyner KA Jr, Swaim MW.
35. Ascites fluid as a possible origin for hy- perfibrinolysis in advanced liver disease. Am J Gastroenterol. 2000; 95: 3218-3224.
36. Spadaro A, Tortorella V, Morace C, For- tiguerra A, Composto P, Bonfiglio C et al. High circulating D-dimers are associ- ated with ascites and hepatocellular car- cinoma in liver cirrhosis. World J Gastro- enterol. 2008 Mar 14; 14(10): 1549-1552.
37. Toschi V, Rocchini GM, Motta A, Fiorini GF, Cimminiello C,Violi F et al. The hyperfibrinolytic state of liver cirrho- sis: possible pathogenetic role of asci- tes. Biomed Pharmacother. 1993; 47: 345-352.
38. P i s c a g l i a F, D o n at i G, G i a n n i n i R, Bolondi L. Liver cirrhosis, ascites, and hyperfibrinolysis. Am J Gastroenterol. 2001; 96: 3222.